You are here

gene therapy

A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy

A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy

Xconomy

Flag link:

Novartis publishes long-term data from SMA gene therapy

Novartis publishes long-term data from SMA gene therapy

Pharmaforum

Flag link:

Big pharma shied away from gene therapy for years. Academia picked up the slack

Big pharma shied away from gene therapy for years. Academia picked up the slack

BioPharma Dive

academic research

Flag link:

Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients

Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients

Fierce Pharma

Flag link:

In its first use inside the human body, CRISPR genome editing tested as blindness therapy

In its first use inside the human body, CRISPR genome editing tested as blindness therapy

Stat

Flag link:

Hear hear! Ear gene therapy player Akouos draws $105M in fresh capital

Hear hear! Ear gene therapy player Akouos draws $105M in fresh capital

Endpoints

Flag link:

Jim Wilson's gene therapy startup Passage Bio bucks market sentiments, raising upsized $216M IPO

Jim Wilson's gene therapy startup Passage Bio bucks market sentiments, raising upsized $216M IPO

Endpoints

Flag link:

Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%

Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%

Motley Fool

Sangamo Therapeutics

Parkinson's Disease

Alzheimer's disease

Flag link:

BioMarin's Novel Treatment Promises to Disrupt Competitors

BioMarin's Novel Treatment Promises to Disrupt Competitors

Motley Fool

Flag link:

Repligen Signals Gene Therapy Strength With 2019 Earnings Report

Repligen Signals Gene Therapy Strength With 2019 Earnings Report

Motley Fool

Flag link:

FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review

FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review

Motley Fool

priority review

Flag link:

FDA Awards Orphan Drug Designation to Prevail's Gene Therapy for Gaucher Disease

FDA Awards Orphan Drug Designation to Prevail's Gene Therapy for Gaucher Disease

BioSpace

Prevail Therapeutics

Gaucher disease

Flag link:

Upcoming events – Avadel takes on Jazz and Axovant awaits early results

Upcoming events – Avadel takes on Jazz and Axovant awaits early results

EP Vantage

Jazz Pharmaceuticals

Parkinson's Disease

Flag link:

Novartis faces criticism over Zolgensma ‘health lottery’

Novartis faces criticism over Zolgensma ‘health lottery’

PM Live

Flag link:

Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World

Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World

Forbes

Flag link:

Catalent laying out $315M to snatch another gene therapy CDMO

Catalent laying out $315M to snatch another gene therapy CDMO

Fierce Pharma

Paragon Services

Flag link:

FDA Expects Explosion in Gene Therapy Treatments, Updates Review Policy

FDA Expects Explosion in Gene Therapy Treatments, Updates Review Policy

Motley Fool

Flag link:

Deerfield vaults to the top of cell and gene therapy CDMO game with $1.1B facility at Philadelphia's newest biopharma hub

Deerfield vaults to the top of cell and gene therapy CDMO game with $1.1B facility at Philadelphia's newest biopharma hub

Endpoints

Deerfield Management

Flag link:

BioMarin sets gene therapy sights beyond hemophilia

BioMarin sets gene therapy sights beyond hemophilia

BioPharma Dive

Flag link:

Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans

Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans

Xconomy

Flag link:

Pages